Pharmacokinetic-pharmacodynamic modeling of the antitumor effect of TM208 and EGFR-TKI resistance in human breast cancer xenograft mice

AIM: The novel anticancer compound TM208 is an EGFR tyrosine kinase inhibitor (EGFR-TKI). Since the development of resistance to EGFR-TKIs is a major challenge in their clinical usage, we investigated the profiles of resistance following continuous treatment with TM208 in human breast cancer xenogra...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Acta Pharmacol Sin
Autors principals: Ji, Xi-wei, Ji, Shuang-min, Li, Run-tao, Wu, Ke-hua, Zhu, Xiao, Lu, Wei, Zhou, Tian-yan
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group 2016
Matèries:
Original Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4954772/
https://ncbi.nlm.nih.gov/pubmed/27133303
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/aps.2016.40
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars